A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Amgen Inc.0 个研究点目标入组 12,000 人开始时间: 2019年5月29日最近更新: 2023年8月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 12,000

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Key Inclusion Criteria:
•-Subject has provided informed consent prior to initiation of any study specific activities/procedures
•-Adult subjects = 50 years (men) or = 55 years (women) to < 80 years of age (either sex) and meeting lipid criteria
•-Subjects must have an LDL-C = 90 mg/dL (= 2.3 mmol/L) OR non-high density lipoprotein (HDL)-C = 120 mg/dL (= 3.1 mmol/L) OR apolipoprotein B = 80mg/dL (= 1.56 µmol/L)
•1. Lipid entry criteria can be measured up to 3 months prior to screening in the absence of changes to background therapy
•2.Lipid criteria should be assessed after = 2 weeks of stable, optimized lipid-lowering therapy
•3. The most recent results (historical and screening) must be used
•-Diagnostic evidence of at least 1 of the following (A – D) at screening:
•A. Significant coronary artery disease meeting at least 1 of the following criteria:
•1. History of coronary revascularization with multi-vessel coronary disease as evidenced by any of the following:
•(a) percutaneous coronary intervention (PCI) of 2 or more vessels, including branch arteries
•(b) PCI or coronary artery bypass grafting (CABG) with residual =50% stenosis in a separate, unrevascularized vessel, or
•(c) multi-vessel CABG 5 years or more prior to screening
•2. Significant coronary disease without prior revascularization as evidenced by either a = 70% stenosis of at least 1 coronary artery, = 50% stenosis of 2 or more coronary arteries, or = 50% stenosis of the left main coronary artery
•3. known coronary artery calcium score = 100 in subjects without a coronary artery revascularization prior to randomization
•B. Significant atherosclerotic cerebrovascular disease meeting at least 1 of the following criteria:
•1. prior transient ischemic attack with = 50% carotid stenosis
•2. internal or external carotid artery stenosis of = 70% or 2 or more = 50% stenosis
•3. prior internal or external carotid artery revascularization
•C. Significant peripheral arterial disease meeting at least 1 of the following criteria:
•1. = 50% stenosis in a limb artery
•2. history of abdominal aorta treatment (percutaneous and surgical) due to atherosclerotic disease
•3. ankle brachial index (ABI) < 0.85
•D. Diabetes mellitus with at least 1 of the following:
•1. known microvascular disease, defined by diabetic nephropathy or treated retinopathy. Diabetic nephropathy defined as persistent microalbuminuria (urinary albumin to creatinine ratio = 30mg/g) and/or persistent estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 that is not reversible due to an acute illness
•2. chronic daily treatment with an intermediate or long-acting insulin
•3. diabetes diagnosis = 10 years ago
•- At least 1 of the following high risk criteria at screening (most recent lab values within 6 months prior to screening, as applicable):
•1. polyvascular disease, defined as coronary, carotid, or peripheral artery stenosis = 50% in a second distinct vascular location in a patient with coronary, cerebral or peripheral arterial disease (above inclusion criterion A-C)
•2. presence of either diabetes mellitus diabetes or metabolic syndrome in a subject with coronary, cerebral, or peripheral artery disease (above inclusion
•criterion A-C)
•3. at least 1 coronary, carotid, or peripheral artery residual stenosis of = 50% in a patient with diabetes meeting above inclusion criterion D
•4. LDL-C = 130 mg/dL ( = 3.36 mmol/L) OR non-HDL-C = 160 mg/dL (= 4.14 mmol/L), OR apolipoprotein B = 120 mg/dL (2.3 µmol/L) if applica

排除标准

•Subjects are excluded from the study if any of the following criteria apply:
•1. Disease Related
•- MI or stroke prior to randomization
•- CABG < 3 months prior to screening
•- Uncontrolled or recurrent ventricular tachycardia in the absence of an implantable-cardioverter defibrillator
•- Atrial fibrillation or atrial flutter not on anticoagulation therapy (vitamin K antagonist, heparin, low-molecular weight heparin, fondaparinux, or non-Vitamin K antagonist oral anticoagulant)
•- Last measured left-ventricular ejection fraction < 30% or New York Heart Association (NYHA) Functional Class III/IV
•- Planned arterial revascularization
•2. Diagnostic Assessments
•- ?riglycerides =500 mg/dL (5.7 mmol/L) measured up to 3 months prior to screening. The most recent results must be used.
•- End stage renal disease (ESRD), defined as an eGFR < 15 mL/min/1.73 m2 or receiving dialysis measured up to 6 months prior to screening. The most recent results must be used.
•3. Other Medical Conditions
•- Malignancy (except non-melanoma skin cancers, cervical in situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years prior to day 1
•- History or evidence of clinically significant disease (eg, malignancy, respiratory, gastrointestinal, renal or psychiatric disease) or unstable disorder that, in the opinion of the investigator(s), Amgen physician or designee would pose a risk to the patient’s safety or interfere with the study assessments, procedures, completion, or result in a life expectancy of less than 1 year
•-Persistent acute liver disease or hepatic dysfunction, defined as Child Pugh score of C
•4. Prior/Concomitant Therapy
•- Previously received a cholesterol ester transfer protein (CETP) inhibitor (ie, anacetrapib, dalcetrapib, evacetrapib), mipomersen, lomitapide, or has undergone LDL-apheresis in the last 12 months prior to LDL-C screening
•- Previously received or receiving any other therapy to inhibit PCSK9 in the following timeframe prior to screening:
•(a) bococizumab at any time
•(b) evolocumab, alirocumab, or any other monoclonal antibody against PCSK9 within 3 months
•(c) inclisiran within 12 months
•5. Prior/Concurrent Clinical Study Experience
•- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies).
•6. Other Exclusions
•- Female subject is pregnant, had a positive pregnancy test at screening (by a serum pregnancy test and/or urine pregnancy test), breastfeeding, or planning to become pregnant or breastfeed during treatment and for an additional 15 weeks after the last dose of investigational product.
•- Female subjects of childbearing potential unwilling to use 1 acceptable method of effective contraception during treatment and for an additional 15 weeks after the last dose of investigational product.
•- Subject has known sensitivity to any of the products or components to be administered during dosing.
•- Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator’s knowledge.
•- Subject is staff personal directly involved with the study or is a family member of the investigational study staff

研究者

发起方

Amgen Inc.

相似试验

进行中（未招募）

1 期

A Double-blind, Randomized, Placebo-controlled, Multicenter, DoseEscalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction

EUCTR2012-000327-40-HUAmgen Inc.544

进行中（未招募）

不适用

A Double-blind, Randomized, Placebo-controlled, Multicenter Study toAssess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality andMorbidity in Heart Failure (HF) Subjects with Symptomatic Left VentricularSystolic Dysfunction and Anemia. - RED-HF Trial – Reduction of Events with Darbepoetin alfa in Heart Failure Trial

EUCTR2005-005278-59-PTAmgen Inc.3,400

进行中（未招募）

不适用

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

EUCTR2010-021003-24-GRAmgen Inc600

进行中（未招募）

1 期

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart FailureAcute heart failureMedDRA version: 14.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disorders

EUCTR2010-021003-24-BEAmgen Inc600

进行中（未招募）

不适用

EUCTR2005-005278-59-DKAmgen Inc.2,600